Takeda Chooses PRA To Lead Its Revamped Clinical Development Ops
Takeda has chosen US-based PRA Health Sciences to lead its clinical development as part of the Japanese drug maker’s global R&D overhaul aimed at cutting costs and improving efficiency and innovation.
You may also be interested in...
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
Five years ago, pharma was in the throes of a vast cull as the global financial meltdown and the patent cliff combined to create a perfect storm for the industry. In 2009, more than 60,000 job cuts were announced in the sector in the US alone, according to the US outplacement specialist Challenger, Gray & Christmas.